Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
- On track to commence Phase 2 study of Trappsol® Cyclo™ for the treatment of Alzheimer's Disease before year end - Continued execution on advancement of lead development program evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1)...
Cyclo Therapeutics to Present at the China NPC Association Meeting
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...
Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...
Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases,...
Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
Presentation by Professor Caroline Hastings, MD, Chair of the Phase 3 Trappsol® Cyclo™ Program Steering Committee and the Global Principal Investigator for the Company's ongoing TransportNPC™ study evaluating Trappsol® Cyclo™ for the...
Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a late clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with...
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
- Continued advancement of lead development program evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) in ongoing global pivotal study (TransportNPC™) - Phase 2 study of Trappsol® Cyclo™ for the treatment of Alzheimer's...
Cyclo Therapeutics to Participate in the Virtual Investor Niemann-Pick Disease Type C Spotlight Event
- Live video webcast with moderated fireside chat with members of the Cyclo Therapeutics leadership team and Global Principal Investigator for the Phase 3 study, Professor Caroline Hastings, MD, on Monday, May 16th at 2:00 PM ET GAINESVILLE, Fla. - Cyclo Therapeutics,...
Cyclo Therapeutics to Participate in the Virtual Investor Alzheimer’s Disease Spotlight Event
- Live video webcast with moderated fireside chat with members from the Cyclo Therapeutics management team and featuring Key Opinion Leader, Cynthia A. Lemere, PhD on Tuesday, April 5th at 1:00 PM ET GAINESVILLE, Fla. - Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo...
Cyclo Therapeutics Enters Research and Collaboration Agreement with Wits Commercial Enterprise (Pty) Ltd to Explore Potential Applications of Trappsol® Cyclo™ to Expand Pipeline
- Collaboration with the University of the Witwatersrand, Johannesburg ("Wits"), represented by Wits Commercial Enterprise; a wholly-owned subsidiary of the University mandated to manage and commercialize the University's Intellectual Property; expected to explore the...